Impact of durable response of first-line systemic treatment for patients with locally advanced or metastatic urothelial carcinoma: data update of EV-302/KEYNOTE-A39 trial.

Miyake M

doi:10.21037/tau-2025-587

← 뒤로

Impact of durable response of first-line systemic treatment for patients with locally advanced or metastatic urothelial carcinoma: data update of EV-302/KEYNOTE-A39 trial.

Translational andrology and urology 2025 Vol.14(12) p. 3799-3805

Miyake M

PMC 전문 ↗ 원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Miyake M (2025). Impact of durable response of first-line systemic treatment for patients with locally advanced or metastatic urothelial carcinoma: data update of EV-302/KEYNOTE-A39 trial.. Translational andrology and urology, 14(12), 3799-3805. https://doi.org/10.21037/tau-2025-587

MLA Miyake M. "Impact of durable response of first-line systemic treatment for patients with locally advanced or metastatic urothelial carcinoma: data update of EV-302/KEYNOTE-A39 trial.." Translational andrology and urology, vol. 14, no. 12, 2025, pp. 3799-3805.

PMID 41522307

DOI 10.21037/tau-2025-587

같은 제1저자의 인용 많은 논문 (2)

[A Case of Robot-Assisted Total Pelvic Organ Resection for Locally Advanced Rectal Cancer for the Elderly].
Gan to kagaku ryoho. Cancer & chemotherapy 2025
[Reconstructive surgery of the nasolacrimal duct and its variations].
Ganka. Ophthalmology 1971